蛋白酪氨酸激酶抑制剂的研究进展  

Progress on the research of protein tyrosine kinase inhibitors

作　　者：赵欣[1] 郭长彬[1] 周化[1] 

机构地区：[1]首都师范大学化学系,北京100048

出　　处：《中国药物化学杂志》2010年第5期442-449,共8页Chinese Journal of Medicinal Chemistry

摘　　要：蛋白酪氨酸激酶(PTK)抑制剂是一类作用于细胞信号转导通路的分子靶向药物,针对特定靶点发挥抗肿瘤作用。目前已有十余种蛋白酪氨酸激酶抑制剂上市,且它们在多种实体瘤的治疗中显示出较好的疗效。该文对近年来蛋白酪氨酸激酶抑制剂的研究进展做简要综述。Protein tyrosine kinase inhibitors are a kind of molecular-targeted agents acting on the cell signal transduction pathway,and play their antitumor role in the appropriate targets.More than ten of such inhibitors have been revealed to be potent on solid tumors and approved by FDA.Recent advances on protein tyrosine kinase inhibitors are reviewed in this paper.

关 键 词：蛋白酪氨酸激酶 抗肿瘤药物 单克隆抗体 小分子蛋白酪氨酸激酶抑制剂 

分 类 号：R979.1[医药卫生—药品]